Harrison K L, Alpers C E, Davis C L
Department of Medicine, University of Washington School of Medicine, Seattle.
Am J Kidney Dis. 1993 Sep;22(3):468-76. doi: 10.1016/s0272-6386(12)70155-5.
Recurrent amyloidosis is an uncommon but well-documented event in up to 26% of renal allograft recipients transplanted for amyloid renal disease. Both primary and secondary amyloidoses recur. De novo primary and secondary amyloid have not been previously reported. We report the first occurrence of de novo secondary amyloid in a renal allograft recipient. The cause of the secondary amyloidosis is unproven, but possible etiologies include inflammation secondary to occult hepatitis, rheumatoid arthritis, or chronic rejection. Colchicine therapy has not resulted in decreased proteinuria or improved renal function.
复发性淀粉样变性在因淀粉样肾病接受肾移植的受者中并不常见，但有充分文献记载，发生率高达26%。原发性和继发性淀粉样变性均可复发。此前尚未报道过新发原发性和继发性淀粉样变性。我们报告了首例肾移植受者新发继发性淀粉样变性。继发性淀粉样变性的病因尚未得到证实，但可能的病因包括隐匿性肝炎、类风湿关节炎或慢性排斥反应继发的炎症。秋水仙碱治疗并未使蛋白尿减少或肾功能改善。
